FDA Brief

Warning letters Drugs

FDA warning letter to

Yangzhou Hongshengding Chemical Co., Ltd.

High riskIssued Jun 15Posted Jun 30Center for Drug Evaluation and Research (CDER)

Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.

What happened

FDA reviewed import records showing multiple shipments of over-the-counter drug products into the U.S. that named YHC as the manufacturer. FDA sent records requests on January 20, February 4, and March 2, 2026, to the registration email and U.S. Agent; the firm did not respond, and did not meet an extended February 17, 2026 deadline. FDA cited refusal to provide access to or copying of required records.

What FDA found

  1. The company refused to let FDA access or copy records required under the federal Food, Drug, and Cosmetic Act.

    Section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a)
  2. The company did not answer repeated FDA requests for records and information under section 704(a)(4).

    Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))

What FDA wants

FDA asks the company to respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, with FEI 3013166766 and ATTN: Ernest Bizjak in the subject line. The company may provide information for FDA to consider or request an FDA inspection.

Who should pay attention

  • U.S. importers and distributors of over-the-counter drugs
  • brands that buy OTC drug products from this manufacturer
  • companies relying on this firm as a registered drug manufacturer

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk